Nanobiotix SA

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

17 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at Upcoming Investor Conferences in March

06 Mar 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Feb 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

31 Jan 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

29 Jan 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Jan 2024 16:32:08 By Nasdaq GlobeNewswire

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

26 Dec 2023 02:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Dec 2023 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

04 Dec 2023 16:16:59 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

13 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

09 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Closing of Global Offering

07 Nov 2023 16:01:02 By Nasdaq GlobeNewswire

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

06 Nov 2023 02:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

02 Nov 2023 10:49:35 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

01 Nov 2023 18:32:02 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

23 Oct 2023 02:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Oct 2023 16:27:41 By Nasdaq GlobeNewswire